Serina Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Mar 25, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 25, 2026
SER$1.43+3.6%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Signatures
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report on Form 10-K to be signed on its behalf by the undersigned, thereunto duly authorized.
Date: March 25, 2026
| SERINA THERAPEUTICS, INC. | |
| By: | /s/ Steve Ledger |
| Steve LedgerChief Executive Officer |
| Signature | Title | Date |
|---|---|---|
| /s/ Balkrishan (Simba) Gill | Executive Chairman of the Board of Directors | March 25, 2026 |
| Balkrishan (Simba) Gill, Ph.D | ||
| /s/ Steve Ledger | Chief Executive Officer and Director | March 25, 2026 |
| Steve Ledger | (Principal Executive Officer) | |
| /s/ Gregory S. Curhan | Chief Financial Officer | March 25, 2026 |
| Gregory S. Curhan | (Principal Financial and Accounting Officer) | |
| /s/ Gregory H. Bailey | Director | March 25, 2026 |
| Gregory H. Bailey, M.D. | ||
| /s/ Stephen Brannan | Director | March 25, 2026 |
| Stephen Brannan, M.D. | ||
| /s/ Richard Marshall | Director | March 25, 2026 |
| Richard Marshall, CBE, M.D., Ph.D. | ||
| /s/ Jay Venkatesan | Director | March 25, 2026 |
| Jay Venkatesan, M.D. | ||
| /s/ Karen J. Wilson | Director | March 25, 2026 |
| Karen J. Wilson | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.